Serotonin transmembrane transporter is down-regulated in late-stage canine degenerative mitral valve disease

Journal of Veterinary Cardiology

Volumn 12, Issue 3, 2010, Pages 163-169

  Scruggs, Sarah M ^a   Disatian, Sirilak ^a   Orton, E Christopher ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

); Mitral valve disease; Serotonin; Serotonin transmembrane transporter (SERT

Indexed keywords

SEROTONIN TRANSPORTER;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CADAVER; CONTROLLED STUDY; DEGENERATIVE MITRAL VALVE DISEASE; DISEASE SEVERITY; DOG; ENDOTHELIUM CELL; FEMALE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; MALE; MITRAL VALVE; MITRAL VALVE DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION;

ANIMALS; DOG DISEASES; DOGS; DOWN-REGULATION; FEMALE; HEART VALVE DISEASES; IMMUNOBLOTTING; MALE; MITRAL VALVE; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

ANIMALIA;

EID: 78649908999     PISSN: 17602734     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvc.2010.06.002     Document Type: Article

References (24)

1. J.E. Rush Chronic valvular disease in dogs J.D. Bonagura, D.C. Twedt, Kirk's current veterinary therapy XIV 2009 Sauders Elsevier 780 786
2. J. Haggstrom, C. Kvart, and H.D. Pedersen Acquired valvular disease S.J. Ettinger, E.C. Feldman, Textbook of veterinary internal medicine 6th ed 2005 Elsevier St Louis 1022 1039
3. J.W. Buchanan Chronic valvular disease (endocardiosis) in dogs Adv Vet Sci Comp Med 21 1977 75 106
4. P.A. Robiolio, V.H. Rigolin, J.S. Wilson, J.K. Harrison, L.L. Sanders, T.M. Bashore, and J.M. Feldman Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography Circulation 92 1995 790 795
5. D.J. Fox, and R.S. Khattar Carcinoid heart disease: presentation, diagnosis, and management Heart 90 2004 1224 1228
6. B.I. Gustafsson, K. Tommeras, I. Nordrum, J.P. Loennechen, A. Brunsvik, E. Solligrd, R. Fossmark, I. Bakke, U. Syversen, and H. Waldum Long-term serotonin administration induces heart valve disease in rats Circulation 111 2005 1517 1522
7. C.S. Elangbam, L.E. Job, L.M. Zadrozny, J.C. Barton, L.W. Yoon, L.D. Gates, and N. Slocum 5-Hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats Exp Toxicol Pathol 60 2008 253 262
8. H.M. Connolly, J.L. Crary, M.D. McGoon, D.D. Hensrud, B.S. Edwards, W.D. Edwards, and H.V. Schaff Valvular heart disease associated with fenfluramine-phentermine N Engl J Med 337 1997 581 588
9. V. Setola, S.J. Hufeisen, K.J. Grande-Allen, I. Vesely, R.A. Glennon, B. Blough, R.B. Rothman, and B.L. Roth 3,4-methylenedioxymethamphetamine (MDMA, ''Ecstasy'') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro Mol Pharmacol 63 2003 1223 1229
10. M.A. Oyama, and S.V. Chittur Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease Am J Vet Res 67 2006 1307 1318
11. J.W. Arndt, C.A. Reynolds, J.M. Singletary, R.J. Levy, and M.A. Oyama Serum serotonin concentrations in dogs with degenerative mitral valve disease J Vet Intern Med 23 2009 1208 1213
12. M.A. Oyama, and R.J. Levy Insights into serotonin signaling in mechanisms associated with canine degenerative mitral valve disease J Vet Intern Med 24 2009 27 36
13. S. Disatian, and E.C. Orton Autocrine serotonin and transforming growth factor α1 signaling mediates spontaneous myxomatous mitral valve disease J Heart Valve Dis 18 2009 44 51
14. S. Disatian, C. Lacerda, and E.C. Orton Tryptophan hydroxylase 1 expression is increased on phenotype-altered canine and human degenerative myxomatous mitral valves J Heart Valve Dis 19 2010 71 78
15. B. Brenner, J.T. Harney, B.A. Ahmed, B.C. Jeffus, R. Unal, J.L. Mehta, and F. Kilic Plasma serotonin levels and the platelet serotonin transporter J Neurochem 102 2007 206 215
16. W. Ni, and S.W. Watts 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT) Clin Exp Pharmacol Physiol 33 2006 575 583
17. A. Mekontso-Dessap, F. Brouri, O. Pascal, P. Lechat, N. Hanoun, L. Lanfumey, I. Seif, N. Benhaiem-Sigaux, M. Kirsch, M. Hamon, S. Adnot, and S. Eddahibi Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice Circulation 113 2006 81 89
18. S. Disatian, E.J. Ehrhart 3rd, S. Zimmerman, and E.C. Orton Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation J Heart Valve Dis 17 2008 402 411
19. F. Côté, E. Thévenot, C. Fligny, Y. Fromes, M. Darmon, M.A. Ripoche, E. Bayard, N. Hanoun, F. Saurini, P. Lechat, L. Dandolo, M. Hamon, J. Mallet, and G. Vodjdani Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function Proc Natl Acad Sci 100 2000 13525 13530
20. D.V. Simula, W.D. Edwards, H.D. Tazelaar, H.M. Connolly, and H.V. Schaff Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years Mayo Clin Proc 77 2002 139 147
21. K.B. Donnelly Cardiac valvular pathology: Comparative pathology and animal models of acquired cardiac valvular diseases Toxicol Pathol 36 2008 204 217
22. E.A. Waller, and J. Kaplan Pergolide-associated valvular heart disease Compr Ther 32 2006 94 101
23. M. Hendrikx, J. Van Dorpe, W. Flameng, and W. Daenen Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature J Heart Valve Dis 5 1996 235 237
24. C. Hofmann, U. Penner, R. Dorow, H.H. Pertz, S. Janichen, R. Horowski, K.P. Latte, D. Palla, and B. Schurad Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis Clin Neuropharmacol 29 2006 80 86